Étiquette : dépression

Cannabinoids and their therapeutic applications in mental disorders, Maria Scherma et al., 2022

Cannabinoids and their therapeutic applications in mental disorders Maria Scherma, PhD; Anna Lisa Muntoni, MD; Gernot Riedel, PhD; Walter Fratta, PhD; Paola Fadda, PhD Dialogues in Clinical Neuroscience, 2020, 22, (3), 271-279. doi : 10.31887/DCNS.2020.22.3/pfadda   Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the [...]

Lire la suite

Cannabis and Depression, Daniel Feingold & Aviv Weinstein, 2021

Cannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]

Lire la suite

Three New Studies on Cannabis and PTSD, Nate Seltenrich, 2022

THREE NEW STUDIES ON CANNABIS AND PTSD Growing numbers of trauma sufferers are medicating with cannabis and finding it helpful. NATE SELTENRICH 31 décembre 2022 In recent years, psilocybin and MDMA have been explored as potential treatments for post-traumatic stress disorder, but somewhat more quietly so has cannabis. In fact, according to a few quick searches of PubMed, cannabis has a longer and richer association with PTSD in the scientific literature than any psychedelic. Though you wouldn’t know that by reading the headlines. Setting aside for a minute how effective psychedelics may or may not be as breakthrough treatments for PTSD, there’s no doubt that [...]

Lire la suite

Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD, Murkar et al., 2022

Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD A. Murkar, T. Kendzerska, J. Shlik, L. Quilty, M. Saad and R. Robillard BMC Psychiatry, 2022, 22, 554 Doi : 10.1186/s12888-022-04185-7   Abstract Background: Some evidence suggests substance use affects clinical outcomes in people with posttraumatic stress disorder (PTSD). However, more work is required to examine links between mental health and cannabis use in PTSD during exposure to external stressors such as the COVID-19 pandemic. This study assessed mental health factors in individuals with self-reported PTSD to: (a) determine whether stress, anxiety, and depression symptoms were associ- ated with changes [...]

Lire la suite

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists, Gniewko Wieckiewicz et al., 2022,

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists Gniewko Wieckiewicz, Iga Stokłosa, Maciej Stokłosa, Piotr Gorczyca and Robert Pudlo Frontiers in Psychiatry, March 2022 | Volume 13 | Article 837946 doi : 10.3389/fpsyt.2022.837946   Cannabis sativa, whose flowers are also known as marijuana or marihuana, is a recreational plant that contains many chemicals that are constantly being studied by scientists around the world. One of these substances is cannabidiol (CBD), which has gained widespread popularity on the internet as a cure for mental health problems, leading many people to use CBD to self-treat depression and anxiety. This [...]

Lire la suite

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer, Stephen Ross et al., 2021

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer Stephen Ross, Gabrielle Agin-Liebes, Sharon Lo, Richard J. Zeifman, Leila Ghazal, Julia Benville, Silvia Franco Corso, Christian Bjerre Real, Jeffrey Guss, Anthony Bossis, and Sarah E. Mennenga ACS Pharmacology & Translational Science, 2021, 4, 553−562. doi : 10.1021/acsptsci.1c00020   ABSTRACT: People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed [...]

Lire la suite

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder : Prospective 12-month follow-up, Natalie Gukasyan et al., 2022

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder : Prospective 12-month follow-up Natalie Gukasyan, Alan K Davis, Frederick S Barrett, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson and Roland R Griffiths Journal of Psychopharmacology, 2022, Vol. 36(2) 151–158. Doi : 10.1177/02698811211073759   Abstract Background : Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims : This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods : This randomized, waiting-list controlled study [...]

Lire la suite

Psychedelic science in post-COVID-19 psychiatry, J. R. Kelly et al., 2020

Psychedelic science in post-COVID-19 psychiatry J. R. Kelly, M. T. Crockett, L. Alexander, M. Haran, A. Baker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2020, 1-6. doi:10.1017/ipm.2020.94   The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are pre- dicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition [...]

Lire la suite

Effectiveness of Psilocybin on Depression : A Qualitative Study, Redhwan Ahmed Al-Naggar et al., 2021

Effectiveness of Psilocybin on Depression : A Qualitative Study Redhwan Ahmed Al-Naggar, Hisham Alshaikhli, Gwen Erlam Electronic Journal of General Medicine, 2021, 18, (3), em296. doi : 10.29333/ejgm/10862   ABSTRACT Introduction : Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. Objective : The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. Method : A qualitative study was conducted interviewing ten participants currently taking psilocybin while experiencing depression and/or anxiety. Ethical approval was obtained from the University ethics committee. Participants were recruited [...]

Lire la suite

The effects of psilocybin on cognitive and emotional functions in healthy participants : Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation, James J Rucker et al., 2021

The effects of psilocybin on cognitive and emotional functions in healthy participants : Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation James J Rucker, Lindsey Marwood, Riikka-Liisa J Ajantaival, Catherine Bird, Hans Eriksson, John Harrison, Molly Lennard-Jones, Sunil Mistry, Francesco Saldarini, Susan Stansfield, Sara J Tai, Sam Williams, Neil Weston, Ekaterina Malievskaia and Allan H Young     Abstract Background : Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim : The aim of this study was to [...]

Lire la suite